246 related articles for article (PubMed ID: 29674440)
1. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Stefoni V; Pellegrini C; Broccoli A; Baldini L; Tani M; Cencini E; Figuera A; Ansuinelli M; Bernocco E; Cantonetti M; Cox MC; Ballerini F; Rusconi C; Visco C; Arcaini L; Fama A; Marasca R; Volpetti S; Castellino A; Califano C; Cavaliere M; Gini G; Liberati AM; Musuraca G; Lucania A; Ricciuti G; Argnani L; Zinzani PL
Oncologist; 2018 Sep; 23(9):1033-1038. PubMed ID: 29674440
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
4. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
5. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE
Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract][Full Text] [Related]
8. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
[TBL] [Abstract][Full Text] [Related]
9. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
10. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A; Petrillo A; Della Pia A; Lee GG; Gill S; Varughese T; Zenreich J; Gutierrez M; Zhang J; Ahn J; Bharani V; Nejad AS; Pascual L; Feldman TA; Leslie LA; Goy AH
Leuk Lymphoma; 2023 Dec; 64(14):2225-2235. PubMed ID: 37740588
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
13. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
15. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
17. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide for mantle cell lymphoma.
Skarbnik AP; Goy AH
Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective.
Lakshmaiah KC; Rachan Shetty KS; Sathyanarayanan V; Lokanatha D; Abraham LJ; Babu KG
J Cancer Res Ther; 2015; 11(4):857-61. PubMed ID: 26881531
[TBL] [Abstract][Full Text] [Related]
20. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.
Broccoli A; Casadei B; Morigi A; Sottotetti F; Gotti M; Spina M; Volpetti S; Ferrero S; Spina F; Pisani F; Merli M; Visco C; Paolini R; Zilioli VR; Baldini L; Di Renzo N; Tosi P; Cascavilla N; Molica S; Ilariucci F; Rigolin GM; D'Alò F; Vanazzi A; Santambrogio E; Marasca R; Mastrullo L; Castellino C; Desabbata G; Scortechini I; Trentin L; Morello L; Argnani L; Zinzani PL
Oncotarget; 2018 May; 9(34):23443-23450. PubMed ID: 29805746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
